Cell and Gene Therapy CRO Market

Cell and Gene Therapy CRO Market (4th Edition): Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy (CAR-NK, CAR-T, TCR-T, and Others), Type of Genetic Modification (Ex vivo and In vivo), Stage of Development (Discovery, Preclinical, and Clinical), Therapeutic Area (Blood Disorders, Cardiovascular Disorders, Dermatological Disorders, Immunological Disorders, Infectious Diseases, Metabolic Disorders, Musculoskeletal Disorders, Neurological Disorders, Oncological Disorders, Rare Diseases, and Other disorders), End-Users (Industry Players and Non-Industry Players) and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    681

  • Pages
    343

  • View Count
    35437

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates

3.2.2. Currency Coverage and Foreign Exchange Rates
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk

3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
4.1 Chapter Overview

5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Contract Research Organizations (CROs)
5.3. Classification of CROs
5.4. Evolution of CROs
5.5. Modern CROs and Prevalent Outsourcing Trends
5.6. Type of Services Offered by CROs
5.7. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
5.8. Advantages of Outsourcing Operations to CROs
5.9. Risks Associated with Outsourcing to CROs
5.10. Future Perspectives

6. GUIDE TO OUTSOURCING
6.1. Chapter Overview
6.2. Cell and Gene Therapy Research: Need for Outsourcing
6.3. Outsourcing Models
6.3.1. Transactional Outsourcing Model
6.3.2. Performance-based Business Model
6.3.3. Outcome-based Business Model
6.3.4. Staff Augmentation Model
6.3.5. Phase-Dependent Outsourcing Model

6.4. Selecting an Appropriate Outsourcing Model
6.5. Selecting a CRO Partner

6.6. Role of CROs in Drug Development
6.6.1. Discovery and Preclinical Research
6.6.2. Early Clinical Research
6.6.3. Clinical Research and Laboratory Services
6.6.4. Key Considerations for Outsourcing Cell and Gene Therapy Operations

6.7. Concluding Remarks

7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Cell and Gene Therapy CROs: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Area of Expertise
7.2.5. Analysis by Type of Cell Therapy
7.2.6. Analysis by Scale of Operation
7.2.7. Analysis by Type of Preclinical Services Offered
7.2.8. Analysis by Type of Clinical Services Offered
7.2.9. Analysis by Type of Regulatory Services Offered
7.2.10. Analysis by Type of General Support Services Offered

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Aixial
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook

8.3. Altasciences
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Recent Developments and Future Outlook

8.4. CMIC
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. ICON
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Recent Developments and Future Outlook

8.6. Labcorp
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook

8.7. Linical
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook

8.8. Medpace
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook

8.9. Novotech
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. Recent Developments and Future Outlook

8.10. PPD
8.10.1. Company Overview
8.10.2. Service Portfolio
8.2.9.3. Recent Developments and Future Outlook

8.11. Precision for Medicine
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. Recent Developments and Future Outlook

8.12. QPS
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.3. Recent Developments and Future Outlook

8.13. Syneos Health
8.13.1. Company Overview
8.13.2. Financial Information
8.13.3. Service Portfolio
8.13.4. Recent Developments and Future Outlook

9. BENCHMARKING ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Cell and Gene Therapy CROs: Benchmark Analysis
9.3.1. Benchmarking Analysis of Small Players based in North America (Peer Group I)
9.3.2. Benchmarking Analysis of Mid-sized Players based in North America (Peer Group II)
9.3.3. Benchmarking Analysis of Large and Very Large Players based in North America (Peer Group III)
9.3.4. Benchmarking Analysis of Small Players based in Europe (Peer Group IV)
9.3.5. Benchmarking Analysis of Mid-sized Players based in Europe (Peer Group V)
9.3.6. Benchmarking Analysis of Large and Very Large Players based in Europe (Peer Group VI)
9.3.7. Benchmarking Analysis of Small, Mid-sized, Large and Very Large Players based in Asia-Pacific (Peer Group VII)
9.3.8. Benchmarking Analysis of Small and Mid-sized Players based in Rest of the World (Peer Group VIII)

9.4. Concluding Remarks

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell and Gene Therapy Contract Research Organizations: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Area of Expertise
10.3.5. Most Active Players: Analysis by Number of Partnerships

10.3.6. Analysis by Geography
10.3.6.1. Intracontinental and Intercontinental Agreements
10.3.6.2. Local and International Agreements

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Merger and Acquisition Models
11.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
11.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
11.3.2. Analysis by Type of Agreement
11.3.3. Analysis by Key Value Drivers
11.3.4. Analysis by Year of Agreement and Key Value Drivers
11.3.5. Most Active Acquirers: Analysis by Number of Acquisitions

11.3.6. Analysis by Geography
11.3.6.1. Local and International Mergers and Acquisitions
11.3.6.2. Intracontinental and Intercontinental Mergers and Acquisitions

11.3.7. Key Acquisitions: Deal Multiples

12. KEY ACQUISITION TARGETS
12.1. Chapter Overview
12.2. Key Assumptions and Parameters
12.3. Scope and Methodology
12.4. Potential Strategic Acquisition Targets Amongst Small Players
12.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapy: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Trial Registration Year and Trial Status
13.3.4. Analysis by Trial Phase
13.3.5. Analysis by Trial Registration Year and Trial Phase
13.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
13.3.7. Analysis of Enrolled Patient Population by Trial Status
13.3.8. Analysis of Enrolled Patient Population by Trial Phase
13.3.9. Analysis by Therapeutic Area
13.3.10. Analysis by Study Design
13.3.11. Analysis by Type of Sponsor / Collaborator
13.3.12. Most Active Industry Players: Analysis by Number of Registered Trials
13.3.13. Analysis of Number of Registered Trials by Geography
13.3.14. Analysis of Number of Registered Trials by Trial Status and Geography
13.3.15. Analysis of Enrolled Patient Population by Geography
13.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography

13.4. Gene Therapy: Clinical Trial Analysis
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Status
13.4.3. Analysis by Trial Registration Year and Trial Status
13.4.4. Analysis by Trial Phase
13.4.5. Analysis by Trial Registration Year and Trial Phase
13.4.6. Analysis of Enrolled Patient Population by Trial Registration Year
13.4.7. Analysis of Enrolled Patient Population by Trial Status
13.4.8. Analysis of Enrolled Patient Population by Trial Phase
13.4.9. Analysis by Therapeutic Area
13.4.10. Analysis by Study Design
13.4.11. Analysis by Type of Sponsor / Collaborator
13.4.12. Most Active Industry Players: Analysis by Number of Registered Trials
13.4.13. Analysis of Number of Registered Trials by Geography
13.4.14. Analysis of Number of Registered Trials by Trial Status and Geography
13.4.15. Analysis of Enrolled Patient Population by Geography
13.4.16. Analysis of Enrolled Patient Population by Trial Status and Geography

14. TOTAL COST OF OWNERSHIP
14.1 Chapter Overview
14.2. Assumptions and Methodology
14.3. Key Parameters
14.4 Total Cost of Ownership (Sample Dataset)
14.4.1 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20
14.4.2. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX, Y0
14.4.3. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by OPEX, Y1-Y20

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Concluding Remarks

16. GLOBAL CELL AND GENE THERAPY CRO MARKET
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Cell and Gene Therapy CRO Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.1. Scenario Analysis
16.3.1.1. Conservative Scenario
16.3.2.2 Optimistic Scenario

16.4. Key Market Segmentations

17. CELL AND GENE THERAPY CRO MARKET, BY TYPE OF CELL THERAPY
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cell and Gene Therapy CRO Market: Distribution by Type of Cell Therapy, 2018, 2024 and 2035
17.3.1. CAR-T: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.2. TCR-T: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.2. CAR-NK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.3. Others: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

17.4. Data Triangulation and Validation

18. CELL AND GENE THERAPY CRO MARKET, BY TYPE OF GENETIC MODIFICATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cell and Gene Therapy CRO Market: Distribution by Type of Genetic Modification, 2018, 2024 and 2035
18.3.1. Ex vivo: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2. In vivo: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18.4. Data Triangulation and Validation

19. CELL AND GENE THERAPY CRO MARKET, BY STAGE OF DEVELOPMENT
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cell and Gene Therapy CRO Market: Distribution by Stage of Development, 2018, 2024 and 2035
19.3.1. Clinical: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.2. Preclinical: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.3. Discovery: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

19.4. Data Triangulation and Validation

20. CELL AND GENE THERAPY CRO MARKET, BY THERAPEUTIC AREA
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Cell and Gene Therapy CRO Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
20.3.1. Oncological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2. Rare Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3. Neurological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.4. Metabolic Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.5. Musculoskeletal Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.6. Cardiovascular Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.7. Immunological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.8. Dermatological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.9. Infectious Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.10. Blood Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.11. Other Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

20.4. Data Triangulation and Validation

21. CELL AND GENE THERAPY CRO MARKET, BY END-USERS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Cell and Gene Therapy CRO Market: Distribution by End-users, 2018, 2024 and 2035
21.3.1. Industry Players: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
21.3.2. Non-Industry Players: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

21.4. Data Triangulation and Validation

22. CELL AND GENE THERAPY CRO MARKET, BY KEY GEOGRAPHICAL REGIONS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Cell and Gene Therapy CRO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
22.3.1. North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.1. US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.2. Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.3. Rest of North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.3.2. Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.1. Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.2. France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.3. UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.4. Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.5. Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.6. Russia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.7. Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.3.3. Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.1. China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.2. Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.3. South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.4. India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.5. Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.6. Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.3.4. Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
 
22.4. Data Triangulation and Validation and Validation

23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Aixial
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Victor Iorgulescu, Business Development Executive

23.3. Gsap
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Mor Moshe, Clinical Trial Manager

23.4. CATO SMS
23.4.1. Company Snapshot
23.4.2. Interview Transcript: Jessica Bliven (Former Director, Marketing and Sales)

23.5. Anonymous Company
23.5.1. Company Snapshot
23.5.2. Interview Transcript: Rhonda Henry, Former President

24. CONCLUDING REMARKS
24.1 Chapter Overview

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: CROs Market Landscape (I /II)
Figure 4.2 Executive Summary: CROs Market Landscape (II /II)
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Mergers and Acquisitions
Figure 4.5 Executive Summary: Cell Therapy Clinical Trial Analysis
Figure 4.6 Executive Summary: Gene Therapy Clinical Trial Analysis
Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Stages of the Drug Development Process
Figure 5.2 Type of Services Offered by CROs
Figure 5.3 Classification of ATMPs
Figure 5.4 Types of Cells Incorporated in Cell Therapy Medicinal Products
Figure 5.5 Advantages of Outsourcing Operations to CROs
Figure 5.6 Risks Associated with Outsourcing to CROs
Figure 6.1 Outsourcing Models
Figure 6.2 Key Characteristics of Transactional Outsourcing Model
Figure 6.3 Key Characteristics of Performance -based Business Model
Figure 6.4 Role of a CRO in Different Phases of Drug Development
Figure 6.5 Key Considerations for Outsourcing Cell and Gene Therapy Operations
Figure 7.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Figure 7.2 Cell and Gene Therapy CROs: Distribution by Company Size
Figure 7.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region)
Figure 7.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country)
Figure 7.5 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Figure 7.6 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Figure 7.7 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Figure 7.8 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Services Offered
Figure 7.9 Cell and Gene Therapy CROs: Distribution by Type of Clinical Services Offered
Figure 7.10 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Services Offered
Figure 7.11 Cell and Gene Therapy CROs: Distribution by Type of General Services Offered
Figure 8.1 CMIC: Annual Revenues, FY 2018-Q1 FY 2024 (JPY Billion)
Figure 8.2 Labcorp: Annual Revenues, FY 2018- FY 2023 (USD Billion)
Figure 8.3 Linical: Annual Revenues, FY 2021- H1 FY 2024 (JPY Million)
Figure 8.4 Medpace: Annual Revenues, FY 2018-FY 2023 (USD Million)
Figure 8.5 Syneos Health: Annual Revenues, FY 2018-3M FY 2023 (USD Billion)
Figure 9.1 Benchmark Analysis: Distribution of Players by Location of Headquarters and Company Size
Figure 9.2 Benchmarking Analysis: Small Players Based in North America (Peer Group I)
Figure 9.3 Benchmarking Analysis: Mid-Sized Players Based in North America (Peer Group II)
Figure 9.4 Benchmarking Analysis: Large and Very Large Players Based in North America (Peer Group III)
Figure 9.5 Benchmarking Analysis: Small Players Based in Europe (Peer Group IV)
Figure 9.6 Benchmarking Analysis: Mid-sized Players Based in Europe (Peer Group V)
Figure 9.7 Benchmarking Analysis: Large and Very Large Players Based in Europe (Peer Group VI)
Figure 9.8 Benchmarking Analysis: Small, Mid-sized, Large and Very Large Players Based in Asia-Pacific (Peer Group VII)
Figure 9.9 Benchmarking Analysis: Small and Mid-sized Players Based in Rest of the World (Peer Group VIII)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Area of Expertise
Figure 10.5 Most Active Players: Distribution by Number of Partnerships
Figure 10.6 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 10.7 Partnerships and Collaborations: Local and International Agreements
Figure 11.1 Mergers and Acquisitions: Cumulative Year-wise Trend, 2015-2023
Figure 11.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 11.3 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 11.4 Mergers and Acquisitions: Distribution by Year of Agreement and Key Value Drivers
Figure 11.5 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 11.6 Local and International Mergers and Acquisitions
Figure 11.7 Intercontinental and Intracontinental Mergers and Acquisitions
Figure 11.8 Mergers and Acquisitions: Deal Multiples Based on Revenues
Figure 13.1 Clinical Trial Analysis for Cell Therapies: Scope and Methodology
Figure 13.2 Clinical Trial Analysis for Gene Therapies: Scope and Methodology
Figure 13.3 Clinical Trial Analysis for Cell Therapies: Cumulative Year-wise Trend, 2018-2023
Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.5 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year andTrialStatus, 2018-2023
Figure 13.6 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Figure 13.7 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year andTrialPhase, 2018-2023
Figure 13.8 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient PopulationbyTrialRegistration Year, 2018-2023
Figure 13.9 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient PopulationbyTrialStatus
Figure 13.10 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.11 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
Figure 13.12 Clinical Trial Analysis for Cell Therapies: Distribution by Study Design
Figure 13.13 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor / Collaborator
Figure 13.14 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 13.15 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Registered Trials by Geography
Figure 13.16 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Registered Trials by Trial Status and Geography
Figure 13.17 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Geography
Figure 13.18 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 13.19 Clinical Trial Analysis for Gene Therapies: Cumulative Year-wise Trend, 2018-2024
Figure 13.20 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.21 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Trial Status, 2018-2024
Figure 13.22 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Figure 13.23 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Trial Phase, 2018-2024
Figure 13.24 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year, 2018-2024
Figure 13.25 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
Figure 13.26 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.27 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Figure 13.28 Clinical Trial Analysis for Gene Therapies: Distribution by Study Design
Figure 13.29 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor / Collaborator
Figure 13.30 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 13.31 Clinical Trial Analysis for Gene Therapies: Distribution of Number of Registered Trials by Geography
Figure 13.32 Clinical Trial Analysis for Gene Therapies: Distribution of Number of Registered Trials by Trial Status and Geography
Figure 13.33 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Geography
Figure 13.34 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 14.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 14.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 14.3 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20 (USD Million)
Figure 14.4 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0: Distribution of CAPEX
Figure 14.5 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 15.1 Cell and Gene Therapy Service Providers: SWOT Analysis
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Global Cell and Gene Therapy CRO Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 16.2 Global Cell and Gene Therapy CRO Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
Figure 16.3 Global Cell and Gene Therapy CRO Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
Figure 17.1 Cell and Gene Therapy CRO Market: Distribution by Type of Cell Therapy, 2018, 2024 and 2035
Figure 17.2 Cell and Gene Therapy CRO Market for CAR-T, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.3 Cell and Gene Therapy CRO Market for TCR-T, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.4 Cell and Gene Therapy CRO Market for CAR-NK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.5 Cell and Gene Therapy CRO Market for Others, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 18.1 Cell and Gene Therapy CRO Market: Distribution by Type of Genetic Modification, 2018, 2024 and 2035
Figure 18.2 Cell and Gene Therapy CRO Market for Ex vivo, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 18.3 Cell and Gene Therapy CRO Market for In vivo, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.1 Cell and Gene Therapy CRO Market: Distribution by Stage of Development, 2018, 2024 and 2035
Figure 19.2 Cell and Gene Therapy CRO Market for Clinical, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.3 Cell and Gene Therapy CRO Market for Preclinical, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.4 Cell and Gene Therapy CRO Market for Discovery, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.1 Cell and Gene Therapy CRO Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
Figure 20.2 Cell and Gene Therapy CRO Market for Oncological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.3 Cell and Gene Therapy CRO Market for Rare Diseases, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.4 Cell and Gene Therapy CRO Market for Neurological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.5 Cell and Gene Therapy CRO Market for Metabolic Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.6 Cell and Gene Therapy CRO Market for Musculoskeletal Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.7 Cell and Gene Therapy CRO Market for Cardiovascular Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.8 Cell and Gene Therapy CRO Market for Immunological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.9 Cell and Gene Therapy CRO Market for Dermatological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.10 Cell and Gene Therapy CRO Market for Infectious Diseases, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.11 Cell and Gene Therapy CRO Market for Blood Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.12 Cell and Gene Therapy CRO Market for Other Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.1 Cell and Gene Therapy CRO Market: Distribution by End-users, 2018, 2024 and 2035
Figure 21.2 Cell and Gene Therapy CRO Market for Industry Players, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.3 Cell and Gene Therapy CRO Market for Non-Industry Players, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.1 Cell and Gene Therapy CRO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 22.2 Cell and Gene Therapy CRO Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.3 Cell and Gene Therapy CRO Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.4 Cell and Gene Therapy CRO Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.5 Cell and Gene Therapy CRO Market in Rest of North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.6 Cell and Gene Therapy CRO Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.7 Cell and Gene Therapy CRO Market in Spain, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.8 Cell and Gene Therapy CRO Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.9 Cell and Gene Therapy CRO Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.10 Cell and Gene Therapy CRO Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.11 Cell and Gene Therapy CRO Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.12 Cell and Gene Therapy CRO Market in Russia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.13 Cell and Gene Therapy CRO Market in Rest of Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.14 Cell and Gene Therapy CRO Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.15 Cell and Gene Therapy CRO Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.16 Cell and Gene Therapy CRO Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.17 Cell and Gene Therapy CRO Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.18 Cell and Gene Therapy CRO Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.19 Cell and Gene Therapy CRO Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.20 Cell and Gene Therapy CRO Market in Rest of Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.21 Cell and Gene Therapy CRO Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-
Figure 24.1 Concluding Remarks: Overall Market Landscape
Figure 24.2 Concluding Remarks: Partnerships and Collaborations
Figure 24.3 Concluding Remarks: Mergers and Acquisitions
Figure 24.4 Concluding Remarks: Clinical Trial Analysis for Cell Therapies
Figure 24.5 Concluding Remarks: Clinical Trial Analysis for Gene Therapies
Figure 24.6 Concluding Remarks: Market Sizing and Opportunity Analysis (I / II)
Figure 24.7 Concluding Remarks: Market Sizing and Opportunity Analysis (II / II)

List Of Tables

Table 5.1 List of Approved ATMP Products
Table 6.1 Attributes of Transactional Outsourcing Model
Table 7.1 List of Cell and Gene Therapy CROs
Table 7.2 Cell and Gene Therapy CROs: Information on Scale of Operation
Table 7.3 Cell and Gene Therapy CROs: Information on Type of Preclinical Services Offered
Table 7.4 Cell and Gene Therapy CROs: Information on Type of Clinical Services Offered
Table 7.5 Cell and Gene Therapy CROs: Information on Type of Regulatory Services Offered
Table 7.6 Cell and Gene Therapy CROs: Information on Type of General Services Offered
Table 8.1 Cell and Gene Therapy CROs: List of Companies Profiled
Table 8.2 Aixial: Company Overview
Table 8.3 Aixial: Service Portfolio
Table 8.4 Altasciences: Company Overview
Table 8.5 Altasciences: Service Portfolio
Table 8.6 Altasciences: Recent Developments and Future Outlook
Table 8.7 CMIC: Company Overview
Table 8.8 CMIC: Service Portfolio
Table 8.9 CMIC: Recent Developments and Future Outlook
Table 8.10 ICON: Company Overview
Table 8.11 ICON: Service Portfolio
Table 8.12 ICON: Recent Developments and Future Outlook
Table 8.13 Labcorp: Company Overview
Table 8.14 Labcorp: Service Portfolio
Table 8.15 Labcorp: Recent Developments and Future Outlook
Table 8.16 Linical: Company Overview
Table 8.17 Linical: Service Portfolio
Table 8.18 Linical: Recent Developments and Future Outlook
Table 8.19 Medpace: Company Overview
Table 8.20 Medpace: Service Portfolio
Table 8.21 Novotech: Company Overview
Table 8.22 Novotech: Service Portfolio
Table 8.23 Novotech: Recent Developments and Future Outlook
Table 8.24 PPD: Company Overview
Table 8.25 PPD: Service Portfolio
Table 8.26 PPD: Recent Developments and Future Outlook
Table 8.27 Precision for Medicine: Company Overview
Table 8.28 Precision for Medicine: Service Portfolio
Table 8.29 Precision for Medicine: Recent Developments and Future Outlook
Table 8.30 QPS: Company Overview
Table 8.31 QPS: Service Portfolio
Table 8.32 QPS: Recent Developments and Future Outlook
Table 8.34 Syneos Health: Company Overview
Table 8.35 Syneos Health: Service Portfolio
Table 8.36 Syneos Health: Recent Developments and Future Outlook
Table 9.1 Benchmark Analysis: Information on Peer Groups
Table 10.1 Cell and Gene Therapy CRO: List of Partnerships and Collaborations, 2015-2023
Table 10.2 Partnerships and Collaborations: Information on Type of Agreement
Table 11.1 Cell and Gene Therapy CROs: List of Mergers and Acquisitions, 2015-2023
Table 11.2 Cell and Gene Therapy CRO Mergers and Acquisitions: Information on Key Value Drivers and Area of Expertise, 2015-2023
Table 11.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2023
Table 12.1 Potential Strategic Acquisition Targets Amongst Small Players
Table 12.2 Potential Strategic Acquisition Targets Amongst Mid-sized Players
Table 14.1 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 23.1 Aixial: Company Snapshot
Table 23.2 Gsap: Company Snapshot
Table 23.3 CATO SMS: Company Snapshot
Table 23.4 Anonymous Company: Company Snapshot
Table 25.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Table 25.2 Cell and Gene Therapy CROs: Distribution by Company Size
Table 25.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region)
Table 25.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country)
Table 25.5 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Table 25.6 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Table 25.7 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Table 25.8 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Services Offered
Table 25.9 Cell and Gene Therapy CROs: Distribution by Type of Clinical Services Offered
Table 25.10 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Services Offered
Table 25.11 Cell and Gene Therapy CROs: Distribution by Type of General Services Offered
Table 25.12 CMIC: Annual Revenues, FY 2018-Q1 FY 2024 (JPY Billion)
Table 25.13 Labcorp: Annual Revenues, FY 2018- FY 2023 (USD Billion)
Table 25.14 Linical: Annual Revenues, FY 2021-H1 FY 2024 (JPY Million)
Table 25.15 Medpace: Annual Revenues, FY 2018-FY 2023 (USD Million)
Table 25.16 Syneos Health: Annual Revenues, FY 2018-3M FY 2023 (USD Billion)
Table 25.17 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
Table 25.18 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2023
Table 25.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 25.21 Partnerships and Collaborations: Distribution by Area of Expertise
Table 25.22 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 25.23 Partnerships and Collaborations: Local and International Agreements
Table 25.24 Most Active Players: Distribution by Number of Partnerships
Table 25.25 Mergers and Acquisitions: Cumulative Year-wise Trend, 2015-2023
Table 25.26 Mergers and Acquisitions: Distribution by Type of Agreement
Table 25.27 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 25.28 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 25.29 Most Active Acquirers: Distribution by Number of Acquisitions
Table 25.30 Mergers and Acquisitions: Intercontinental and Intracontinental
Table 25.31 Mergers and Acquisitions: Local and International
Table 25.32 Mergers and Acquisitions: Deal Multiples Based on Revenues
Table 25.33 Clinical Trial Analysis for Cell Therapies: Cumulative Year-wise Trend, 2018-2023
Table 25.34 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 25.35 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year andTrialStatus
Table 25.36 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Table 25.37 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year andTrialPhase,
Table 25.38 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient PopulationbyTrialReg
Table 25.39 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
Table 25.40 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 25.41 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
Table 25.42 Clinical Trial Analysis for Cell Therapies: Distribution by Study Design
Table 25.43 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor / Collaborator
Table 25.44 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.45 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Registered Trials by Geography
Table 25.46 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Registered Trials by Trial Status and Geography
Table 25.47 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Geography
Table 25.48 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 25.49 Clinical Trial Analysis for Gene Therapies: Cumulative Year-wise Trend, 2018-2024
Table 25.50 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 25.51 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Trial Status, 2018-2024
Table 25.52 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Table 25.53 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Trial Phase, 2018-2024
Table 25.54 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year, 2018-2024
Table 25.55 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
Table 25.56 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 25.57 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Table 25.58 Clinical Trial Analysis for Gene Therapies: Distribution by Study Design
Table 25.59 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor / Collaborator
Table 25.60 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.61 Clinical Trial Analysis for Gene Therapies: Distribution of Number of Registered Trials by Geography
Table 25.62 Clinical Trial Analysis for Gene Therapies: Distribution of Number of Registered Trials by Trial Status and Geography
Table 25.63 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Geography
Table 25.64 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 25.65 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20 (USD Million)
Table 25.66 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0: Distribution of CAPEX
Table 25.67 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 25.68 Global Cell and Gene Therapy CRO Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.69 Global Cell and Gene Therapy CRO Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
Table 25.70 Global Cell and Gene Therapy CRO Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
Table 25.71 Cell and Gene Therapy CRO Market: Distribution by Type of Cell Therapy, 2018, 2024 and 2035
Table 25.72 Cell and Gene Therapy CRO Market for CAR-T, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.73 Cell and Gene Therapy CRO Market for TCR-T, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.74 Cell and Gene Therapy CRO Market for CAR-NK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.75 Cell and Gene Therapy CRO Market for Others, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.76 Cell and Gene Therapy CRO Market: Distribution by Type of Genetic Modification, 2018, 2024 and 2035
Table 25.77 Cell and Gene Therapy CRO Market for Ex vivo, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.78 Cell and Gene Therapy CRO Market for In vivo, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.79 Cell and Gene Therapy CRO Market: Distribution by Stage of Development, 2018, 2024 and 2035
Table 25.80 Cell and Gene Therapy CRO Market for Clinical, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.81 Cell and Gene Therapy CRO Market for Preclinical, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.82 Cell and Gene Therapy CRO Market for Discovery, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.83 Cell and Gene Therapy CRO Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
Table 25.84 Cell and Gene Therapy CRO Market for Oncological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.85 Cell and Gene Therapy CRO Market for Rare Diseases, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.86 Cell and Gene Therapy CRO Market for Neurological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.87 Cell and Gene Therapy CRO Market for Metabolic Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.88 Cell and Gene Therapy CRO Market for Musculoskeletal Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.89 Cell and Gene Therapy CRO Market for Cardiovascular Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.90 Cell and Gene Therapy CRO Market for Immunological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.91 Cell and Gene Therapy CRO Market for Dermatological Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.92 Cell and Gene Therapy CRO Market for Infectious Diseases, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.93 Cell and Gene Therapy CRO Market for Blood Disorders Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.94 Cell and Gene Therapy CRO Market for Other Disorders, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.95 Cell and Gene Therapy CRO Market: Distribution by End-users, 2018, 2024 and 2035
Table 25.96 Cell and Gene Therapy CRO Market for Industry Players, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.97 Cell and Gene Therapy CRO Market for Non-Industry Players, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.98 Cell and Gene Therapy CRO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Table 25.99 Cell and Gene Therapy CRO Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.100 Cell and Gene Therapy CRO Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.101 Cell and Gene Therapy CRO Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.102 Cell and Gene Therapy CRO Market in Rest of North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.103 Cell and Gene Therapy CRO Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.104 Cell and Gene Therapy CRO Market in Spain, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.105 Cell and Gene Therapy CRO Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.106 Cell and Gene Therapy CRO Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.107 Cell and Gene Therapy CRO Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.108 Cell and Gene Therapy CRO Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.109 Cell and Gene Therapy CRO Market in Russia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.110 Cell and Gene Therapy CRO Market in Rest of Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.111 Cell and Gene Therapy CRO Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.112 Cell and Gene Therapy CRO Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.113 Cell and Gene Therapy CRO Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.114 Cell and Gene Therapy CRO Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.115 Cell and Gene Therapy CRO Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.116 Cell and Gene Therapy CRO Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 25.117 Cell and Gene Therapy CRO Market in Rest of Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table25.118 Cell and Gene Therapy CRO Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. 4Clinics
  2. AbbVie
  3. Absorption Systems (Acquired by Pharmaron)
  4. Accelera
  5. AccelLAB
  6. Accellacare
  7. Accelovance
  8. Accelsiors
  9. Advanced BioScience Laboratories
  10. Advanced Cell Diagnostics
  11. Aginko Research
  12. Aixial 
  13. Allucent (Formally known as CATO SMS)
  14. Altasciences
  15. Cencora ( Formally known as AmerisourceBergen) 
  16. Amgen
  17. Amulet Capital Partners
  18. Ankarys Therapeutics 
  19. Applied StemCell
  20. Ascension
  21. Aurigon
  22. Avance Biosciences
  23. Avance Clinical
  24. Avania
  25. Binhui Bio
  26. BioAccess
  27. BioAgilytix
  28. BioAnalytix
  29. Bioheng
  30. BioMarin Pharmaceutical
  31. Biomedical Advanced Research and Development Authority
  32. Biomere
  33. BioRestorative Therapies 
  34. Bio-Techne 
  35. Biotect Services
  36. BioVille 
  37. BrainStorm Cell Therapeutics
  38. Cambridge Biomedical
  39. Catalyst
  40. Cato Research
  41. Cellectar Biosciences
  42. CellProtect Biotechnology
  43. CellTrans
  44. Charles River Laboratories
  45. Chiltern
  46. Chimeric Therapeutics
  47. Citoxlab
  48. City of Hope
  49. Clean Cells
  50. Clinical Network Services (CNS)
  51. CMIC
  52. CombiGene
  53. Comparative Biosciences
  54. Covance
  55. CRC Oncology
  56. Creative Biolabs
  57. Crown Bioscience
  58. Cryoport
  59. CTI Clinical Trial & Consulting Services (CTI)
  60. Datavant
  61. Diamond Pharma Services (Acquired by ProPharma)
  62. DiscGenics
  63. EastHORN (Acquired by Novotech)
  64. EMMES
  65. Envigo
  66. Ergomed
  67. Evotec
  68. Excelya
  69. Fast-Track Drugs and Biologics
  70. FGK Clinical Research
  71. Forge Biologics
  72. Frontage Laboratories
  73. Geistak Pharmaceuticals
  74. Genesis Biotechnology 
  75. GeneWerk
  76. GenoSafe
  77. Genprex
  78. Genpro Research
  79. Global Center for Medical Innovation
  80. Gsap
  81. HebeCell
  82. Helixmith 
  83. HemaCare
  84. HemoGenix
  85. Hull Associates 
  86. ICON
  87. ICRC-Weyer
  88. Imanis Life Sciences
  89. IMARC
  90. Immunicum
  91. IMS Health
  92. INC Research (Acquired by Syneos Health)
  93. Intertek Pharmaceutical Services
  94. inVentiv Health
  95. IPM Biotech
  96. IQVIA
  97. Ironstone Product Development
  98. KCR 
  99. Kuopio Center for Gene and Cell Therapy (KCT)
  100. Klinar CRO
  101. Labcorp
  102. Larix
  103. LatinaBA
  104. Linical Accelovance
  105. Longmore 60 Biotech
  106. Lovelace Biomedical
  107. Lunaphore
  108. MAXIS
  109. MD Anderson Cancer Center 
  110. Medelis
  111. Medidata
  112. Medpace
  113. MetabAxis
  114. MI Bioresearch
  115. MPI Research
  116. NCGS
  117. NeoGenomics
  118. NetValue BioConsulting
  119. Neurocore
  120. NIH
  121. Noble Life Sciences
  122. Novartis Pharmaceuticals
  123. NovaTrials
  124. Novotech
  125. Nuventra
  126. OBiO Technology
  127. OcellO B.V. (Acquired by Crown Bioscience)
  128. OncoBay Clinical
  129. Oncoshot
  130. Parexel
  131. Partex
  132. PathoQuest 
  133. Pfizer
  134. Pharmahungary
  135. PharmaLex
  136. Pharmaron 
  137. Pharmaseed
  138. Pilgrim Quality Solutions
  139. PPD
  140. PRC Clinical
  141. Precision for Medicine
  142. Premier Research
  143. Primera Analytical Solutions
  144. Prolytix
  145. ProPharma 
  146. ProtaGene (Formally known as Protagen Protein Services)
  147. PSI CRO
  148. PSN Research
  149. QbD
  150. QHP Capital
  151. QPS
  152. Q-Trials
  153. Quality Assistance
  154. Radyus Research
  155. regenold
  156. Renova Therapeutics
  157. Research Dynamics
  158. Rocket Pharmaceuticals 
  159. Strategic Preclinical Product Development (S2PD)
  160. Sannova Analytical 
  161. Sanofi
  162. Sarepta Therapeutics
  163. SBH Sciences
  164. Scandinavian CRO
  165. SCiAN Services
  166. Scope International
  167. Sermes CRO
  168. Sernova 
  169. Sinclair Research
  170. SMS-oncology
  171. SNBL USA
  172. SUSMED
  173. Svar Life Science
  174. Syneos Health
  175. Synteract (Acquired by Syneos Health)
  176. TCTC Group
  177. TechnoPharmaSphere
  178. TFS Healthcare
  179. TFS HealthScience
  180. Theradex Oncology
  181. TiGenix
  182. Tofflon
  183. Translational Drug Development (TD2)
  184. Trialbee
  185. Veeva Systems
  186. Veristat
  187. Vial
  188. Vivotecnia
  189. Vyriad
  190. Wake Forest Innovations
  191. WCCT Global
  192. WCG IRB (Formerly known as WIRB)
  193. Worldwide Clinical Trials
  194. Xcell Bioscience

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com